

Osteoarthritis Enrollment Form

Date: _____ Needs by Date: _____

Patients must bring an original prescription to the pharmacy. Faxed prescriptions will only be accepted from a prescribing practitioner.

PATIENT INFORMATION <i>(Complete the following or send patient demographic sheet)</i> Patient Name: _____ Address: _____ City, State, Zip: _____ Home Phone: _____ Alternate Phone: _____ Last Four of SS #: _____ Primary Language: _____ Date of Birth: _____ Gender: _____	PRESCRIBER INFORMATION Prescriber's Name: _____ State License #: _____ UPIN: _____ DEA #: _____ NPI #: _____ Group or Hospital: _____ Address: _____ City, State Zip: _____ Phone: _____ Fax: _____ Contact Person: _____ Phone: _____
--	---

INSURANCE INFORMATION *(Please copy and attach the front and back of insurance and prescription drug card)*

Prescription Card:	Name of Insurer: _____	ID#: _____	BIN: _____	PCN: _____	Group: _____
Primary Insurance:	Subscriber: _____	ID#: _____	Name of Insurer: _____	Phone: _____	
Secondary Insurance:	Subscriber: _____	ID#: _____	Name of Insurer: _____	Phone: _____	

STATEMENT OF MEDICAL NECESSITY

Diagnosis: <input type="checkbox"/> M15.0 Osteoarthritis <input type="checkbox"/> _____ • Date of Diagnosis: _____	Patient Evaluation: • Does the patient have a complete collapse of the joint space or bone loss? <input type="checkbox"/> Yes <input type="checkbox"/> No • Does the patient skin diseases or infection in or around the affected joint? <input type="checkbox"/> Yes <input type="checkbox"/> No • If patient has tried simple analgesics, please name and include strength and duration: _____ _____ • Has patient received previous course of treatment with hyaluronidase? <input type="checkbox"/> Yes <input type="checkbox"/> No • If yes, how long ago? _____ months • Did patient experience pain relief? <input type="checkbox"/> Yes <input type="checkbox"/> No • Does the patient have extensive inflammation with joint effusion or an inflammatory flare? <input type="checkbox"/> Yes <input type="checkbox"/> No • Has the patient been treated with simple analgesics in the past? <input type="checkbox"/> Yes <input type="checkbox"/> No • Unilateral or bilateral treatment? <input type="checkbox"/> unilateral <input type="checkbox"/> bilateral • Patient Weight: _____ kg/lbs • Concomitant Medications: _____ • Allergies: _____
--	--

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
<input type="checkbox"/> Orthovisc®	30mg/2ml Syringe	Inject contents of prefilled syringe intra-articularly once a week for _ weeks.		
<input type="checkbox"/> Include one 20G 1.5" needle per syringe				
<input type="checkbox"/> MonoVisc®	88mg/4ml	Inject contents of prefilled syringe intra-articularly one time		
<input type="checkbox"/> Include one 20G 1.5" needle per syringe/vial				
<input type="checkbox"/> Euflexxa®	20mg/2ml Prefilled Syringe	Inject contents of prefilled syringe intra-articularly once a week for 3 weeks		
<input type="checkbox"/> Include one 20G 1.5" needle per syringe				
<input type="checkbox"/> Supartz®	25mg/2.5ml Prefilled Syringe	Inject contents of prefilled syringe intra-articularly once a week for 5 weeks.		
<input type="checkbox"/> Include one 23G 1.5" needle per syringe				
<input type="checkbox"/> Synvisc One™	48mg/6ml Prefilled Syringe	Inject contents of prefilled syringe intra-articularly one time		
<input type="checkbox"/> Include one 20G 1.5" needle per syringe				
<input type="checkbox"/> Synvisc®	16mg/2ml Prefilled Syringe	Inject contents of prefilled syringe intra-articularly once a week for 3 weeks.		
<input type="checkbox"/> Include one 20G 1.5" needle per syringe				

X _____
 Physician's Signature (Date)

I authorize pharmacy and its representative to act as an agent to initiate and execute the insurance prior authorization process.

IMPORTANT NOTICE: this facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee.